Lisa Burke
Nurse Practitioner · Lees Summit, MONPI 1538699269
Payments from drug & device makers
Across 226 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$887
- Lilly USA, LLC$461
- AstraZeneca$435
- Teva Pharmaceuticals USA, Inc.$251
- Boehringer Ingelheim$251
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$249
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,106100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 42 | $887 |
| Lilly USA, LLC | 28 | $461 |
| AstraZeneca | 18 | $435 |
| Teva Pharmaceuticals USA, Inc. | 12 | $251 |
| Boehringer Ingelheim | 14 | $251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $249 |
| Pfizer | 11 | $179 |
| Novo Nordisk | 7 | $129 |
| Otsuka America Pharmaceutical, Inc. | 7 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $95 |
| Biohaven Pharmaceuticals, Inc. | 5 | $85 |
| Amgen | 6 | $84 |
| GSK | 4 | $65 |
| Bayer | 4 | $63 |
| Merck | 5 | $62 |
| Novartis | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Dexcom, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $40 |
| Almatica Pharma LLC | 2 | $39 |
| Eisai Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $36 |
| Johnson & Johnson | 2 | $33 |
| Boston Scientific | 1 | $31 |
| Medtronic | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Organon | 2 | $14 |
| Phadia US Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,121 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $72,291 |
| AristadaAripiprazole Lauroxil | 13 | $39,515 |
| JardianceEmpagliflozin | 33 | $33,165 |
| MounjaroTirzepatide | 15 | $32,009 |
| TrulicityDulaglutide | 27 | $26,598 |
| EliquisApixaban | 25 | $17,008 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,611 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,501 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,627 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,178 |
| Gabapentin | 228 | $3,844 |
| Omeprazole | 79 | $1,712 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $1,576 |
| Pregabalin | 13 | $1,565 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $129 | $72,29144 claims |
| Lilly USA, LLCMounjaro, Trulicity | $461 | $58,60742 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $251 | $38,79244 claims |
| PfizerEliquis | $179 | $17,00825 claims |
| AstraZenecaSymbicort | $435 | $6,50116 claims |
| GSKBreo Ellipta | $65 | $4,17812 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $251 | $72216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Lees Summit
- Elizabeth BertschyLees Summit$15K
- Melissa WrenLees Summit$10K
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.